SARS-CoV-2 reactive infectious mucocutaneous eruptions in adults treated with cyclosporine as first line treatment

J Dtsch Dermatol Ges. 2024 Jul;22(7):1013-1015. doi: 10.1111/ddg.15417. Epub 2024 Jun 4.

Authors

Andrew McDermid¹, Kaitlyn Lam¹, Yen Chen Kevin Ko², Toby Schmitt², Touraj Khosravi-Hafshejani¹, Jan P Dutz^{1

3}

Affiliations

¹ Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada.
² Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
³ Senior Scientist, BC Children's Hospital Research Institute.

PMID: 38837589
DOI: 10.1111/ddg.15417

No abstract available

Keywords: COVID; RIME; T cell; calcineurin inhibitor.

Publication types

Letter
Case Reports

MeSH terms

Adult
Aged
COVID-19*
Cyclosporine* / adverse effects
Cyclosporine* / therapeutic use
Drug Eruptions / diagnosis
Drug Eruptions / etiology
Female
Humans
Immunosuppressive Agents* / adverse effects
Immunosuppressive Agents* / therapeutic use
Male
Middle Aged
SARS-CoV-2*

Substances

Cyclosporine
Immunosuppressive Agents